| 30/07/26 | 12:00:00 | 30 Jul 2026 | | HUTCHMED Reports 2026 Interim Results | RNS |
| 02/07/26 | 09:30:00 | 2 Jul 2026 | | HUTCHMED Announces NMPA Approval for ORPATHYS | RNS |
| 30/06/26 | 09:30:00 | 30 Jun 2026 | | HUTCHMED to Announce 2026 Half-Year Results | RNS |
| 29/06/26 | 09:30:00 | 29 Jun 2026 | | Announcement on blocklisting six monthly return | RNS |
| 25/06/26 | 07:00:08 | 25 Jun 2026 | | HUTCHMED Highlights Phase II Data at ESMO | RNS |
| 12/06/26 | 07:00:06 | 12 Jun 2026 | | HUTCHMED Highlights Sovleplenib Phase III Data | RNS |
| 05/06/26 | 09:30:00 | 5 Jun 2026 | | Block Admission Application | RNS |
| 22/05/26 | 07:00:06 | 22 May 2026 | | HUTCHMED Highlights Data to be Presented at ASCO | RNS |
| 21/05/26 | 11:00:01 | 21 May 2026 | | NMPA approval for ELUNATE with TYVYT | RNS |
| 12/05/26 | 12:45:00 | 12 May 2026 | | Announcement on Results of Annual General Meeting | RNS |
| 30/04/26 | 09:30:00 | 30 Apr 2026 | | Total Voting Rights | RNS |
| 29/04/26 | 11:00:00 | 29 Apr 2026 | | HUTCHMED Announces NDA Acceptance in China | RNS |
| 09/04/26 | 09:30:00 | 9 Apr 2026 | | 2025 Annual Report and Notice of AGM | RNS |
| 09/04/26 | 07:00:07 | 9 Apr 2026 | | Data to be Presented at AACR Annual Meeting 2026 | RNS |
| 23/03/26 | 07:00:13 | 23 Mar 2026 | | HUTCHMED Initiates Phase III Trial of HMPL-760 | RNS |
| 16/03/26 | 08:30:00 | 16 Mar 2026 | | Vesting of awards under Long Term Incentive Plan | RNS |
| 11/03/26 | 08:30:00 | 11 Mar 2026 | | Vesting of awards under Long Term Incentive Plan | RNS |
| 09/03/26 | 09:30:00 | 9 Mar 2026 | | Update on Licensed Oncology Product in China | RNS |
| 06/03/26 | 08:30:00 | 6 Mar 2026 | | Directorate change | RNS |
| 05/03/26 | 13:00:00 | 5 Mar 2026 | | Publication of Form 20-F | RNS |
| 05/03/26 | 11:00:01 | 5 Mar 2026 | | 2025 Full Year Results and Business Updates | RNS |
| 04/03/26 | 08:30:00 | 4 Mar 2026 | | HUTCHMED Initiates Global Trial of ATTC Candidate | RNS |
| 06/02/26 | 08:30:00 | 6 Feb 2026 | | HUTCHMED to Announce 2025 Final Results | RNS |
| 14/01/26 | 07:00:09 | 14 Jan 2026 | | Publication of Phase III Results in The Lancet | RNS |
| 07/01/26 | 07:00:07 | 7 Jan 2026 | | Positive Topline Results of Phase III Trial | RNS |
| 05/01/26 | 07:00:07 | 5 Jan 2026 | | Surufatinib + Camrelizumab PDAC Phase 3 initiation | RNS |
| 31/12/25 | 07:00:03 | 31 Dec 2025 | | Total Voting Rights | RNS |
| 30/12/25 | 10:00:00 | 30 Dec 2025 | | China NDA Acceptance-Savolitinib in Gastric Cancer | RNS |
| 29/12/25 | 08:30:00 | 29 Dec 2025 | | NDA Acceptance in China for Fanregratinib | RNS |
| 29/12/25 | 08:30:00 | 29 Dec 2025 | | Blocklisting Six Monthly Return | RNS |
| 17/12/25 | 07:00:10 | 17 Dec 2025 | | HUTCHMED Initiates Development of ATTC Candidate | RNS |
| 08/12/25 | 07:00:11 | 8 Dec 2025 | | Expanded NRDL Coverage + CIDL Inclusion in China | RNS |
| 28/11/25 | 08:30:01 | 28 Nov 2025 | | Total Voting Rights | RNS |
| 27/11/25 | 07:00:15 | 27 Nov 2025 | | HUTCHMED Highlights Data at ESMO and ASH | RNS |
| 05/11/25 | 07:00:12 | 5 Nov 2025 | | Enrollment Complete in SAFFRON Global Phase III | RNS |
| 03/11/25 | 07:00:12 | 3 Nov 2025 | | Updates from R&D Event | RNS |
| 23/10/25 | 07:00:10 | 23 Oct 2025 | | HUTCHMED Presents Data at AACR NCI EORTC | RNS |
| 21/10/25 | 09:30:00 | 21 Oct 2025 | | Vesting of awards under Long Term Incentive Plan | RNS |
| 14/10/25 | 09:30:00 | 14 Oct 2025 | | Appointment of Independent Non-executive Director | RNS |
| 13/10/25 | 07:05:14 | 13 Oct 2025 | | Data to be Presented at the 2025 ESMO Congress | RNS |
| 02/10/25 | 07:00:12 | 2 Oct 2025 | | HUTCHMED Highlights Data to be Presented at ESMO | RNS |
| 30/09/25 | 09:30:00 | 30 Sept 2025 | | Total Voting Rights | RNS |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | HUTCHMED to Present R&D Updates on October 31 2025 | RNS |
| 05/09/25 | 07:00:09 | 5 Sept 2025 | | HUTCHMED Highlights Data to be Presented at CSCO | RNS |
| 26/08/25 | 07:00:14 | 26 Aug 2025 | | Directorate Change | RNS |
| 20/08/25 | 07:00:13 | 20 Aug 2025 | | HUTCHMED Completes Enrollment of Phase III Trial | RNS |
| 07/08/25 | 12:00:01 | 7 Aug 2025 | | 2025 Interim Results | RNS |
| 03/07/25 | 09:30:00 | 3 Jul 2025 | | HUTCHMED to Announce 2025 Half-Year Results | RNS |
| 02/07/25 | 10:00:00 | 2 Jul 2025 | | Update on Joint Corporate Brokers in London | RNS |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | China Approval based on Phase III SACHI Trial | RNS |
